Trial watch: Immune checkpoint blockers for cancer therapy

Immune checkpoint blockers (ICBs) are literally revolutionizing the clinical management of an ever more diversified panel of oncological indications. Although considerable attention persists around the inhibition of cytotoxic T lymphocyte-associated protein 4 (CTLA4) and programmed cell death 1 (PDC...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncoimmunology
Hlavní autoři: Vanpouille-Box, Claire, Lhuillier, Claire, Bezu, Lucillia, Aranda, Fernando, Yamazaki, Takahiro, Kepp, Oliver, Fucikova, Jitka, Spisek, Radek, Demaria, Sandra, Formenti, Silvia C., Zitvogel, Laurence, Kroemer, Guido, Galluzzi, Lorenzo
Médium: Artigo
Jazyk:Inglês
Vydáno: Taylor & Francis 2017
Témata:
Review
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5674958/
https://ncbi.nlm.nih.gov/pubmed/29147629
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1373237
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky